Identifying GP2 specific T cell immune response at baseline prior to treatment with GP2 has potential to predict breast cancer recurrence risk and timing of recurrence A positive baseline immune ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback